MRC Technology Appoints General Counsel and Company Secretary
News Feb 04, 2015
MRC Technology (MRCT) has appointed Dr Edward Bliss in the new role of General Counsel and Company Secretary. Edward will join MRCT on 16 March from Shire Pharmaceuticals plc, where he is currently Legal Director.
Prior to that he was the General Counsel and Company Secretary at Ark Therapeutics Group plc and he joined Ark from private practice with the international life sciences law firm Covington and Burling LLP.
A solicitor, Edward also holds a degree in Physiology and PhD in Neuroscience and brings a wealth of experience to the role. His responsibilities will include licensing, governance, compliance, and in-house legal affairs.
Welcoming Edward, Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Ed will be a great asset and we look forward to him joining. Licensing is a key part of our mission to drive scientific research to benefit patients. We have already negotiated over 400 commercial licences and Ed will continue to build on this success.”
Dr Edward Bliss said: “It is a tremendous privilege to be joining MRC Technology and I look forward to working with Dave Tapolczay and his team in their important goal of progressing the further development of innovative medical research.”
Nano-tech Diagnostic Can Indicate Cancer or Thrombotic Risk in One Drop of BloodNews
A team of international researchers led by Professor Martin Hegner, Investigator in CRANN and Trinity’s School of Physics, have developed an automated diagnostic platform that can quantify bleeding – and thrombotic risks – in a single drop of blood, within seconds.READ MORE
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE